^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Design, Synthesis and Assessment of Novel Molecule against Drug-Resistant Dual Mutant EGFR (T790M/L858R) to Treat NSCLC

Published date:
08/08/2023
Excerpt:
Cell-based assays revealed that KKI04 inhibits the H1975 cells (T790M/L858R) with a 2.5 fold higher affinity than Osimertinib with IC50 values 2±0.5µM and 7±0.5µM, respectively...